Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure
Open Access
- 15 July 2004
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 94 (2) , 237-239
- https://doi.org/10.1016/j.amjcard.2004.03.074
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Endothelin Expression and the Progression of Heart FailureCirculation, 2004
- Endothelin A Receptor Antagonism in Experimental Congestive Heart Failure Results in Augmentation of the Renin-Angiotensin System and Sustained Sodium RetentionCirculation, 2004
- Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET A ) Receptor Blockade in Chronic Heart FailureCirculation, 2002
- Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?International Journal of Cardiology, 2002
- Endothelins are potent vasoconstrictors, and much more besidesPublished by Elsevier ,2000
- Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failureEuropean Journal of Clinical Pharmacology, 1996